Holen Sie sich die Stockscreener-App
12.74
1.92%
-0.25
Schlusskurs vom Vortag:
$12.99
Offen:
$13.17
24-Stunden-Volumen:
26,163
Relative Volume:
0.92
Marktkapitalisierung:
$59.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-17.45
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
+16.56%
1M Leistung:
-7.51%
6M Leistung:
+68.11%
1J Leistung:
+92.42%
1-Tages-Spanne:
$12.36
$13.34
1-Wochen-Bereich:
$10.51
$13.34
52-Wochen-Spanne:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
12.74 | 60.98M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bond Watch: Is MiNK Therapeutics Inc. stock in correction or buying zoneJuly 2025 Update & Community Consensus Trade Signals - BỘ NỘI VỤ
Why MiNK Therapeutics Inc. stock is favored by top institutionsWeekly Trading Summary & Community Verified Trade Signals - Newser
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Is MiNK Therapeutics Inc. (6Q40) stock inflation resilientQuarterly Profit Report & Daily Growth Stock Tips - Newser
What downside risks could hit MiNK Therapeutics Inc. (6Q40) stockJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
MiNK Therapeutics (INKT) Stock Analysis Report | Financials & Insights - Benzinga
Why MiNK Therapeutics Inc. (6Q40) stock appeals to dividend investorsQuarterly Trade Summary & Growth Focused Entry Point Reports - Newser
Will MiNK Therapeutics Inc. (6Q40) stock recover faster than industryStock Surge & Momentum Based Trading Signals - Newser
How MiNK Therapeutics Inc. (6Q40) stock compares with tech leaders2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-12-02 06:12:45 - Newser
Will MiNK Therapeutics Inc. (6Q40) stock outperform value peersMarket Activity Recap & Target Return Focused Stock Picks - Newser
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Why MiNK Therapeutics Inc. stock is seen as undervaluedEarnings Recap Report & Real-Time Volume Surge Alerts - moha.gov.vn
Buybacks Report: Why MiNK Therapeutics Inc. stock attracts global investorsM&A Rumor & Risk Managed Investment Signals - BỘ NỘI VỤ
(INKT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
MiNK Therapeutics Inc 6Q40 Stock Analysis and ForecastBull Market Opportunities & Learn From the Strategies of Institutions - earlytimes.in
MiNK Therapeutics Inc Stock Analysis and ForecastSupport Level Holds & Small Capital Trading Plans - earlytimes.in
MiNK Therapeutics announces publication of new preclinical data for MiNK-215 - MSN
How reliable is MiNK Therapeutics Inc. (6Q40) stock dividend growthEarnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - The Manila Times
MiNK Therapeutics Advances iNKT Platform in Q3 2025 - MSN
MiNK Therapeutics Announces New Data Showing MiNK-215 - GlobeNewswire
MiNK Therapeutics (NASDAQ: INKT) unveils MiNK-215 CAR-iNKT for solid tumors - Stock Titan
Why global investors buy MiNK Therapeutics Inc. (6Q40) stock - newser.com
How MiNK Therapeutics Inc. stock performs in rate cut cyclesBond Market & Community Shared Stock Ideas - newser.com
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
FY2025 EPS Forecast for MiNK Therapeutics Lifted by Analyst - MarketBeat
FY2025 EPS Estimate for MiNK Therapeutics Raised by Analyst - Defense World
Will MiNK Therapeutics Inc. stock see insider buyingJuly 2025 Sector Moves & Risk Managed Trade Strategies - newser.com
What’s next for MiNK Therapeutics Inc. stock priceBond Market & Verified Momentum Stock Watchlist - newser.com
Published on: 2025-11-19 15:48:22 - newser.com
Using fundamentals and technicals on MiNK Therapeutics Inc.2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Why analysts remain bullish on MiNK Therapeutics Inc. stockJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Is MiNK Therapeutics Inc. stock safe for conservative investors2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Can MiNK Therapeutics Inc. stock resist sector downturnsTrade Volume Summary & Entry Point Strategy Guides - newser.com
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):